Authors' objectives: To review evidence on the effectiveness, safety and cost-effectiveness of Namyang Ketonia as a ketogenic diet treatment for epilepsy in infant and young children.

Authors' recommendations: There was limited but good level of retrievable evidence on the effectiveness of Namyang Ketonia as a ketogenic diet treatment for epilepsy in infant and young children. All studies seemed to show more than 50% reduction in seizure compared to their comparative controls at three months, and this response was maintained for up to a year. However, the evidence obtained was not properly designed RCTs because studies included are limited by small sample sizes and of short duration. Some studies did not specify the randomisation process, and none were blinded. Outcome measures relating to seizure control such as seizure reduction were not well-defined and specified. There was no retrievable evidence on United States Food and Drug Administration (US FDA) approval or CE mark for this product. Some studies recorded a range of side effects, the most prevalent being gastrointestinal effects.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.moh.gov.my/index.php/database_stores/store_view_page/30/226

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Malaysia

Organisation Name: Malaysian Health Technology Assessment

Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229

Contact Name: htamalaysia@moh.gov.my

Contact Email: htamalaysia@moh.gov.my

Copyright: Malaysian Health Technology Assessment (MaHTAS)